Rapport Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Small Molecule Medicines for CNS & Neurological Disorders
Rapport Therapeutics is a public clinical-stage biotech (Nasdaq: RAPP) developing precision small molecules targeting TARP-containing AMPARs for epilepsy and other CNS disorders; completed $174M IPO in June 2024;
About
Rapport Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts. The company is developing a new class of precision small molecule medicines for neurological and psychiatric disorders by targeting Receptor-Associated Proteins (RAPs) — a family of proteins that modulate the function of ion channels in the brain. Rapport''s lead program, RAP-219, is an investigational small molecule that selectively inhibits TARP-gamma-8-containing AMPA receptors (AMPARs) — a receptor subtype concentrated in the hippocampus and limbic system — for the treatment of focal onset seizures (focal epilepsy) and other CNS conditions driven by hyperexcitability in these circuits.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.